2017
DOI: 10.1080/14656566.2017.1282461
|View full text |Cite
|
Sign up to set email alerts
|

Current and future therapies for the treatment of histamine-induced angioedema

Abstract: Introduction Angioedema, a sudden, self-limited swelling of localized areas of any part of the body that may or may not be associated with urticaria, is thought to be the result of a mast-cell mediated process versus a bradykinin etiology. Understanding the mechanism is key in determining the proper treatment. Areas Covered Clinical presentation of varying angioedema types may be similar; however, the appropriate treatment algorithm is dependent upon clinicians’ knowledge of the underlying pathophysiology an… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
28
0
3

Year Published

2017
2017
2024
2024

Publication Types

Select...
7
1

Relationship

1
7

Authors

Journals

citations
Cited by 25 publications
(31 citation statements)
references
References 61 publications
0
28
0
3
Order By: Relevance
“…Angioedema can be mediated by histamine or bradykinin. Hereditary angioedema (HAE) is bradykinin‐mediated and usually develops over the course of several hours, whereas in CSU, angioedema is histamine‐mediated and develops rapidly . For HAE patients, angioedema episodes can range from a minor inconvenience to life‐threatening episodes, with a mortality rate of approximately 30% in the case of laryngeal edema .…”
Section: Discussionmentioning
confidence: 99%
“…Angioedema can be mediated by histamine or bradykinin. Hereditary angioedema (HAE) is bradykinin‐mediated and usually develops over the course of several hours, whereas in CSU, angioedema is histamine‐mediated and develops rapidly . For HAE patients, angioedema episodes can range from a minor inconvenience to life‐threatening episodes, with a mortality rate of approximately 30% in the case of laryngeal edema .…”
Section: Discussionmentioning
confidence: 99%
“…Some of the immune cells (mast cells), which are located in the submucosa of the pulmonary tract, attack primarily to Coronavirus. [1][2][3][4] First, the virus activates mast cells and then certain chemical compounds are generated against the pathogen. Here, we develop a new idea that inflammation in patients with COVID-19 may be mitigated by both leukotriene modifiers and mast cell stabilizers.…”
Section: Can Leukotriene Modifiers and Mast Cell Stabilizers Decreasementioning
confidence: 99%
“…2 Angiotensin-converting enzyme 2 (ACE-2) inhibitorinduced angioedema could be a mast cell/histaminemediated. 3 Human pathogenic coronaviruses attach to epithelial cells through ACE-2 increased angiotensin-converting enzyme two and expression of ACE-2 in the lung, intestine, kidney and blood vessels facilitates infection. Some of the drugs that stimulate the expression of ACE-2 increase the risk of fatal COVID-19.…”
Section: Can Leukotriene Modifiers and Mast Cell Stabilizers Decreasementioning
confidence: 99%
“…Ürtiker-anjioödem tablolarının %10-15'inde anjioödem yalnız başına bulunmaktadır. 2,14,17 Anjioödem erişkinlerde (40-50 yaş arası) ve kadınlarda daha sıktır. Fakat idiyopatik anjioödem (ürtikersiz) daha sık erkeklerde görülür.…”
Section: Epidemiyolojisi (Genel Prevalans)unclassified
“…Ciltte deskuamasyon ve lekelenme yoktur, fakat kaşımaya bağlı morluk olabilir. Özellikle, MHAAÖ kaşıntıve ürtikerle beraber görülebilir 2,[7][8][9][10][11][12][13][14].…”
unclassified